What CCORN does

CCORN (Community Clinical Oncology Research Network) is a privately held, full-service clinical research organization headquartered in Rock Hill, South Carolina, specializing in hematology and oncology clinical trials and real-world evidence (RWE) studies for pharmaceutical, biotech, and biological sponsors. Founded in 2004 under Dr. Kashyap Patel, the company operates across the Southeast US with multi-state investigator licensing (California, North Carolina, South Carolina) and has supported approximately 40 industry-sponsored trials cumulatively, supported by a research team reporting over 100 years of cumulative PI and Sub-Investigator experience and over 100 peer-reviewed publications. CCORN's stated mission centers on closing disparities in precision medicine and cancer care by distributing trials through a network of community oncology clinics that serve more representative patient populations than traditional academic settings.

The company's service portfolio spans study feasibility, site start-up and management, matrix-based project management, and dedicated RWE and late-phase research teams. CCORN maintains proficiency across five major EDC platforms (iMedidata, MyTrials, TrialMaster, TrialManager, Oracle Inform) and has developed a proprietary EDC build capability for sponsor-specific needs. It operates three proprietary disease registries — RECOMM (multiple myeloma on panobinostat), POEM (febrile neutropenia prophylaxis), and PREFER (advanced-stage cancer biomarker prevalence with a community biobank) — which generate owned real-world evidence assets beyond pure fee-for-service trial execution. Distribution is direct enterprise sales to pharma sponsors, with ecosystem reach extended through partnerships with Labcorp, Sema4, Invitae, and Dr. Patel's Medical Director role at International Oncology Network (ION).

CCORN monetizes through B2B professional-services contracts on a per-study basis, supplemented by managed-services revenue tied to its three registries; pricing is not publicly disclosed. The customer base comprises at least 11 named large-pharma and biotech sponsors (Spectrum, Amgen, Incyte, Novartis, AstraZeneca, Helsinn, Celgene, Biocartis, Biodesix, Heron, Asterand), all enterprise accounts. The firm is founder-led (Dr. Kashyap Patel as CEO, Alpa Patel as co-founder) with no disclosed external funding, parent company, or institutional ownership, and reports a headcount of 1–10 employees, indicating a lean operating model that likely subcontracts significant portions of monitoring and data management.

Name

CCORN

Legal name

Community Clinical Oncology Research Network (CCORN)

Website

https://ccorn.net

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

CCORN is a Rock Hill, South Carolina-based clinical research organization that delivers full-service hematology and oncology clinical trials and real-world evidence studies for pharmaceutical and biotech sponsors, distributing trials through a community clinic network to broaden patient representation.

Ownership category

akta.pro rank

Product category

Clinical Research Organization Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Clinical research organization
• Oncology clinical trials
• Real world evidence studies
• Hematology research services
• Site management services

Headquarters

HQ city

Rock Hill

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Full-service clinical research organization offering services across all clinical phases of development for pharmaceutical and biotech sponsors. Services include study feasibility, site management, study start-up activities, real world evidence and late phase research, project management, and therapeutic area expertise in hematology/oncology.
2. Disease Registry Studies: Management and delivery of Real World Experience (RWE) and Registry studies in entirety for sponsors, including the RECOMM, POEM, and PREFER registries targeting specific disease populations.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

CCORN is a Clinical Research Organization offering full-service experience across all clinical phases of development for pharmaceutical, drug, and biological industry sponsors. Services include study feasibility, site management, study start-up activities, project management, real world evidence and late phase research, and therapeutic area expertise focused on hematology and oncology, with trial distribution through a network of community clinics to reach underrepresented patient populations.

Product overview

CCORN is a Clinical Research Organization offering full-service experience in all clinical phases of development for the pharmaceutical, drug, and biological industry. The company provides an integrated suite of clinical research services including Study Feasibility, Study Start-Up Activities, Project Management, Site Management, Real World Evidence and Late Phase Research, Therapeutic Areas Services, and Community Clinic Integration. The portfolio includes three named patient registries (RECOMM for Multiple Myeloma patients on panobinostat, POEM for febrile neutropenia prophylaxis in non-myeloid malignancies, and PREFER for advanced stage cancer biomarkers). Therapeutic expertise spans Hematology and Oncology with a focus on addressing disparities in clinical research and precision medicine through community clinic integration.

Differentiator

Problem solved

Functional benefit

Products and services

• Study Feasibility Feasibility assessment providing forecasting related to estimation of patients, sites, and time required to deliver studies from start to finish. Helps sponsors identify recruitment projection issues and review the competitive regional landscape, for pharmaceutical, drug, and biological industry sponsors.
• Study Start-Up Activities Expedites site start-up by pre-identifying appropriate sites, maintaining close communication, submitting on the site's behalf, conducting Remote SIV, and managing protocol development, ICF and CRF/eCRF development, clinical development plans, final investigator/site selection, and patient recruitment strategies for pharma and biotech sponsors.
• Project Management Provides quality services and project management using a matrix-based organization model with dedicated professional teams assigned to each study, integrated multi-disciplinary execution of project objectives, and comprehensive project management tools for study management, reporting, and risk mitigation for pharmaceutical and biotech sponsors.
• Site Management Maintains active communication channels with clients to minimize miscommunications. Ensures continuous regulatory documentation updates and maintenance in accordance with regulatory agency guidelines with active communication from startup until publication, for pharmaceutical and biotech sponsors.
• Real World Evidence and Late Phase Research Dedicated RWE and late-phase research teams providing core capabilities for commercial and scientific objectives in hematology and oncology, including registries, health economics, and outcomes research with over 100 years of collective investigator experience, for pharmaceutical and biotech sponsors.
• Therapeutic Areas Services Expert clinical and research services in the hematology/oncology space with an innovative approach to RWE and registry studies, provided to pharmaceutical and biotech sponsors.
• Community Clinic Integration Uses a network of community clinics to distribute trials to appropriate locations. Sites create profiles of physicians with experience ranging from Phase 1 to Registry studies, and patient demographics that more completely represent the cancer patient population, for pharmaceutical and biotech sponsors.
• RECOMM Registry Disease registry encompassing the care of patients with multiple myeloma on panobinostat (Farydak), aiming to describe current treatment patterns in real-world settings and explore associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes, for pharmaceutical and biotech sponsors.
• POEM Registry Disease registry encompassing the care of patients with prophylaxis of febrile neutropenia (FN) related to non-myeloid malignancies, a multicenter prospective observational cohort registry for subjects receiving myelosuppressive chemotherapy at high risk for developing FN, for pharmaceutical and biotech sponsors.
• PREFER Registry Prospective registry of advanced stage cancer patients to assess prevalence of actionable biomarkers and driver mutations using the OmniSeq test, with creation of a biobank from community cancer clinics to address disparities in precision medicine, for pharmaceutical and biotech sponsors.
• Hematology Research Real world evidence clinical research where investigators plan, design, and execute clinical studies ranging from early to late phase studies designed to assess efficacy, identify biological effects, evaluate health economics, and outcomes research in hematologic disorders, for pharmaceutical and biotech sponsors.
• Oncology Research Innovative approach to real world evidence helping get new therapies to cancer patients with better tolerance levels, addressing the unmet medical need for effective therapies driven by global growth in new cancer cases, for pharmaceutical and biotech sponsors.

Quantifiable outcome

• Worked with approximately 40 large and small hematology/oncology focused industry sponsored trials
• +2 more outcomes

Named customers11 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Huyabio InternationalminorStrategic or Co-development PartnerPartner organization shown in CCORN's partner logos section on the projects page. Nature of partnership not explicitly detailed.
• LabcorpminorStrategic or Co-development PartnerPartner organization shown in CCORN's partner logos section. Labcorp is a global life sciences company that may provide laboratory services for clinical trials.
• Sema4minorStrategic or Co-development PartnerPartner organization shown in CCORN's partner logos section. Sema4 is a patient-centered health intelligence company providing biomarker and genomic testing services.
• InvataeminorStrategic or Co-development PartnerPartner organization shown in CCORN's partner logos section. Invatae provides genetic testing and diagnostic services.
• International Oncology Network (ION)coreStrategic or Co-development PartnerDr. Kashyap Patel serves as Medical Director of International Oncology Network. ION is a network of oncology practices and serves as a strategic alliance partner.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medpace: Medpace is a mid-to-large global CRO with a strong reputation in oncology and other therapeutic areas. While much larger, it competes with CCORN for hematology/oncology trial work and represents the type of full-service sponsor a smaller specialty CRO must differentiate against.
• Labcorp Drug Development: Labcorp combines central lab services with a global CRO offering through its Drug Development division. It is both a competitor for oncology trial work and an existing CCORN partner, making it a uniquely positioned broad incumbent.
• IQVIA: IQVIA is the world's largest CRO with a broad oncology franchise and the deepest sponsor relationships globally. It represents the consolidated-vendor threat that could pressure smaller specialty CROs like CCORN out of major oncology programs.
• ICON plc: ICON is one of the largest global CROs with deep oncology capability following its PRA Health Sciences acquisition. It competes with CCORN for biopharma oncology work and offers the geographic scale and integrated lab/biomarker services CCORN cannot.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size global CRO with notable oncology and hematology capability serving biopharma sponsors. Comparable to CCORN in therapeutic focus but operates at a much larger geographic scale.
• PPD (Thermo Fisher Scientific): PPD is a global CRO acquired by Thermo Fisher Scientific, offering full-service oncology clinical development including early and late phase. It competes with CCORN for sponsor hematology/oncology engagements and offers integrated bioanalytical and lab services.

Direct peers

• Velocity Clinical Research: Velocity operates a multi-site clinical research organization network focused on therapeutic-area trials including oncology, with emphasis on community-based access and sponsor trial execution. Comparable to CCORN in target customer (pharma sponsors), therapeutic focus, and community delivery model.
• US Oncology Research: US Oncology Research is a community-based oncology research network within The US Oncology Network, conducting hematology/oncology trials across hundreds of community practice sites. It is structurally the closest competitor to CCORN's community clinic integration model.
• Translational Research in Oncology (TRIO): TRIO is an oncology-focused CRO that runs international clinical trials in breast cancer and other solid tumors, working with pharma sponsors globally. It is comparable to CCORN as a focused oncology CRO, though larger and more international in footprint.
• Sarah Cannon Research Institute: Sarah Cannon is one of the largest oncology-focused clinical research organizations in the US, operating a community-based site network that conducts hematology/oncology trials for biopharma sponsors. CCORN competes directly for the same sponsor oncology trials and shares the same community-site model.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ccorn

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CCORN